BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 20131276)

  • 61. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients.
    Østergaard M; Emery P; Conaghan PG; Fleischmann R; Hsia EC; Xu W; Rahman MU
    Arthritis Rheum; 2011 Dec; 63(12):3712-22. PubMed ID: 22127693
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
    Maini R; St Clair EW; Breedveld F; Furst D; Kalden J; Weisman M; Smolen J; Emery P; Harriman G; Feldmann M; Lipsky P
    Lancet; 1999 Dec; 354(9194):1932-9. PubMed ID: 10622295
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
    Hara M; Ishiguro N; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Yamamoto K;
    Mod Rheumatol; 2014 May; 24(3):410-8. PubMed ID: 24252050
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H
    Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Golimumab for rheumatoid arthritis: a systematic review.
    Singh JA; Noorbaloochi S; Singh G
    J Rheumatol; 2010 Jun; 37(6):1096-104. PubMed ID: 20436075
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
    Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
    Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
    [TBL] [Abstract][Full Text] [Related]  

  • 67. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Vieira-Sousa E; Alves P; Rodrigues AM; Teixeira F; Tavares-Costa J; Bernardo A; Pimenta S; Pimentel-Santos FM; Gomes JL; Aguiar R; Pinto P; Videira T; Catita C; Santos H; Borges J; Sequeira G; Ribeiro C; Teixeira L; Ávila-Ribeiro P; Martins FM; Canhão H; McInnes IB; Ribeiro RM; Fonseca JE
    Ann Rheum Dis; 2020 Apr; 79(4):490-498. PubMed ID: 32193187
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
    Choy E; McKenna F; Vencovsky J; Valente R; Goel N; Vanlunen B; Davies O; Stahl HD; Alten R
    Rheumatology (Oxford); 2012 Jul; 51(7):1226-34. PubMed ID: 22344576
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
    Durez P; Malghem J; Nzeusseu Toukap A; Depresseux G; Lauwerys BR; Westhovens R; Luyten FP; Corluy L; Houssiau FA; Verschueren P
    Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
    van Mens LJJ; de Jong HM; Fluri I; Nurmohamed MT; van de Sande MGH; Kok M; van Kuijk AWR; Baeten D
    Ann Rheum Dis; 2019 May; 78(5):610-616. PubMed ID: 30808625
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
    Fleischmann R; Schiff M; van der Heijde D; Ramos-Remus C; Spindler A; Stanislav M; Zerbini CA; Gurbuz S; Dickson C; de Bono S; Schlichting D; Beattie S; Kuo WL; Rooney T; Macias W; Takeuchi T
    Arthritis Rheumatol; 2017 Mar; 69(3):506-517. PubMed ID: 27723271
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks.
    Takeuchi T; Harigai M; Tanaka Y; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Kanazawa M; Oba T; Yoshinari T; Baker D;
    Ann Rheum Dis; 2013 Sep; 72(9):1488-95. PubMed ID: 22984173
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study.
    Mease PJ; Gladman DD; Keystone EC;
    Arthritis Rheum; 2006 May; 54(5):1638-45. PubMed ID: 16646026
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate.
    Rau R; Simianer S; van Riel PL; van de Putte LB; Krüger K; Schattenkirchner M; Allaart CF; Breedveld FC; Kempeni J; Beck K; Kupper H
    Scand J Rheumatol; 2004; 33(3):145-53. PubMed ID: 15228184
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.